I am a board-certified hematologist specializing in the treatment of multiple myeloma and other plasma cell neoplasms. I have a particular research interest in early plasma cell disorders, including monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM), and understanding disease biology that may promote transition to frank symptomatic multiple myeloma in some individuals. My colleagues at Memorial Sloan Kettering and I offer a variety of treatment options (on and off clinical trial) for patients with multiple myeloma and high-risk SMM, including access to the latest novel drugs and immune-therapeutic approaches. Recent therapeutic advances have led to improved outcomes for people with multiple myeloma, and I am working on developing methods of monitoring minimal residual disease. By understanding mechanisms of tumor resistance with current available drugs and monitoring techniques, we aim to drive myeloma research forward and develop new strategies of tumor control or eradication.